Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

179162

registered interest
date	11/02/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Mental Health Services: North East
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what the average waiting time is for mental health talking therapies in (a) Hartlepool constituency and (b) the North East.
tabling member constituency	Hartlepool
tabling member printed	Mr Iain Wright
uin	224147
answer	answer is ministerial correction date of answer 24/02/2015 answer text <p>The information is not available in the format requested. Such information as is available is shown in the following table. The Improving Access to Psychological Therapies (IAPT) dataset contains information on referrals to IAPT services which provide talking therapies. Information is provided both for Hartlepool and Stockton-on-Tees Clinical Commissioning Groups (CCG) and for all 12 North East CCGs combined for the year 2013/14. Hartlepool and Stockton-on-Tees CCG includes Hartlepool constituency and the CCG is the smallest geographical breakdown available.</p><p> </p><p><strong> </strong></p><p> </p><table><tbody><tr><td colspan="4"><p>The number of referrals entering treatment<sup>1</sup> in the year, with mean and median waiting times (days), for IAPT services in 2013/14. Data shown for NHS Hartlepool and Stockton-on-Tees CCG and all North East CCGs combined<sup>2</sup>.</p></td><td><p> </p></td></tr><tr><td><p>Organisation name</p></td><td><p>Referrals entering treatment</p></td><td><p>Mean<sup>3</sup> waiting time to first treatment appointment (days)</p></td><td><p>Median<sup>3</sup> waiting time to first treatment appointment (days)</p></td><td><p> </p></td></tr><tr><td> </td><td> </td><td> </td><td> </td><td><p> </p></td></tr><tr><td><p>NHS Hartlepool and Stockton-on-Tees CCG</p></td><td><p>7,050</p></td><td><p>27</p></td><td><p>11</p></td><td><p> </p></td></tr><tr><td> </td><td> </td><td> </td><td> </td><td><p> </p></td></tr><tr><td><p>All North East CCGs combined</p></td><td><p>50,845</p></td><td><p>25</p></td><td><p>11</p></td><td><p> </p></td></tr><tr><td><p> </p></td><td><p> </p></td><td><p> </p></td><td><p> </p></td><td><p> </p></td></tr><tr><td> </td><td> </td><td> </td><td> </td><td><p> </p></td></tr><tr><td colspan="5"><p><sup>1</sup>In order to enter treatment a referral must have a first treatment appointment (an appointment with a therapy type recorded) in the year.</p></td></tr><tr><td colspan="5"><p><sup>2</sup>CCG is based on general practitioner (GP) Practice. Where GP Practice is not recorded, or cannot be assigned to a CCG, the referral is categorised as 'Unknown'.</p></td></tr><tr><td colspan="3"><p><sup>3</sup>Means and medians have been rounded to the nearest whole number.</p></td><td> </td><td> </td></tr></tbody></table><p> </p><p> </p><p> </p><p><em>Notes:</em></p><p> </p><p>Waiting time is measured by counting the number of days between a referral being received and the first treatment appointment. For 2013/14, the presence of a valid therapy type is used as an indicator of whether treatment was provided in the course of the appointment.</p><p> </p><p> </p><p> </p><p>Entering treatment figures are rounded to the nearest 5.</p><p> </p><p> </p><p> </p><p>It is generally advised that the median is used as the more reliable measure of average waiting time, as this accounts better for any outliers in the data.</p><p> </p><p><em> </em></p><p> </p><p><em>Source:</em> IAPT Dataset, Health and Social Care Information Centre</p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb question first answered 24/02/2015 14:40:57 answering member 1439 label Biography information for Norman Lamb
tabling member	1478 label Biography information for Mr Iain Wright

179176

registered interest
date	11/02/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how many commissioning fact sheets have been produced by NHS England since 2013; and what plans NHS England has to produce a commissioning fact sheet for dermatology services.
tabling member constituency	Nottingham South
tabling member printed	Lilian Greenwood
uin	224232
answer	answer is ministerial correction date of answer 23/02/2015 answer text <p>Since 1 April 2013, NHS England has published information factsheets for a range of purposes. The main factsheet resource for commissioners has been produced to provide the costs and benefits of 25 specific interventions to reduce premature deaths:</p><p> </p><p> </p><p> </p><p><a href="http://www.england.nhs.uk/ourwork/forward-view/sop/red-prem-mort/factsheets/" target="_blank">www.england.nhs.uk/ourwork/forward-view/sop/red-prem-mort/factsheets/</a></p><p> </p><p> </p><p> </p><p>Although there are currently no plans to produce a commissioning factsheet for dermatology, National Institute for Health and Care Excellence guidance in areas such as eczema and psoriasis continues to help commissioners to deliver high quality dermatological care.</p><p> </p><p> </p><p> </p><p>With regard to strategic clinical networks (SCNs), the first SCNs were chosen by NHS England using criteria developed with input from a broad range of stakeholders. These are initial groupings and it is expected that they will be expanded in the future. NHS England is undertaking a review of the role, purpose and function of the sub-regional infrastructure that it funds, which is focussed on supporting commissioners and providers to improve the quality of services including SCNs. This review is ongoing and is expected to reach its conclusions by the end of March.</p><p> </p><p> </p><p> </p><p>NHS England currently has no plans to introduce a National Clinical Director for Dermatology. However, NHS England has established a clinical reference group for specialised dermatology to bring together clinical experts, patients and carers to share best practice and improve services for patients.</p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb grouped question UIN 224234 224258 question first answered 23/02/2015 17:01:54 answering member 1439 label Biography information for Norman Lamb
tabling member	4029 label Biography information for Lilian Greenwood

179310

registered interest
date	11/02/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Anaemia
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, pursuant to the Answer of 10 Febraury 2015 to Question 223094, what assessment he has made of the implications for his policies of the findings by the Pernicious Anaemia Society members' survey, published in the British Journal of Nursing in April 2014, that over 60 per cent of people with pernicious anaemia are unhappy with their treatment and that many such people self-medicate to reduce their pain; and if he will consider the potential merits of revising the relevant guidelines to recommend more regular treatment.
tabling member constituency	Ealing, Southall
tabling member printed	Mr Virendra Sharma
uin	224293
answer	answer is ministerial correction date of answer 24/02/2015 answer text <p>The treatment of pernicious anaemia, the result of a vitamin B12 (cobalamin) deficiency, is well established and reported in the British Committee for Standards in Haematology (BCSH) document, <em>Guidelines for the diagnosis and treatment of Cobalamin and Folate disorders</em>, which was updated in May 2014. The BCSH operates independently of the Department and NHS England.</p><p> </p><p> </p><p> </p><p>Current clinical practice within the United Kingdom is to treat pernicious anaemia with Vitamin B12 intramuscular injections. The BCSH produces evidence based guidelines for both clinical and laboratory haematologists on the diagnosis and treatment of haematological disease, drawing on the advice of expert consultants and clinical scientists practicing in the United Kingdom. The guidelines can be found via the BCSH website at the following link:</p><p> </p><p> </p><p> </p><p><a href="http://www.bcshguidelines.com/" target="_blank">www.bcshguidelines.com</a></p><p> </p><p> </p><p> </p><p>Any patient with pernicious anaemia who has concerns about their treatment should discuss this matter with their general practitioner.</p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb question first answered 24/02/2015 13:57:27 answering member 1439 label Biography information for Norman Lamb
tabling member	1604 label Biography information for Mr Virendra Sharma

179321

registered interest
date	11/02/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Dermatology
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment he has made of the potential merits of introducing a National Clinical Director for Dermatology.
tabling member constituency	Nottingham South
tabling member printed	Lilian Greenwood
uin	224258
answer	answer is ministerial correction date of answer 23/02/2015 answer text <p>Since 1 April 2013, NHS England has published information factsheets for a range of purposes. The main factsheet resource for commissioners has been produced to provide the costs and benefits of 25 specific interventions to reduce premature deaths:</p><p> </p><p> </p><p> </p><p><a href="http://www.england.nhs.uk/ourwork/forward-view/sop/red-prem-mort/factsheets/" target="_blank">www.england.nhs.uk/ourwork/forward-view/sop/red-prem-mort/factsheets/</a></p><p> </p><p> </p><p> </p><p>Although there are currently no plans to produce a commissioning factsheet for dermatology, National Institute for Health and Care Excellence guidance in areas such as eczema and psoriasis continues to help commissioners to deliver high quality dermatological care.</p><p> </p><p> </p><p> </p><p>With regard to strategic clinical networks (SCNs), the first SCNs were chosen by NHS England using criteria developed with input from a broad range of stakeholders. These are initial groupings and it is expected that they will be expanded in the future. NHS England is undertaking a review of the role, purpose and function of the sub-regional infrastructure that it funds, which is focussed on supporting commissioners and providers to improve the quality of services including SCNs. This review is ongoing and is expected to reach its conclusions by the end of March.</p><p> </p><p> </p><p> </p><p>NHS England currently has no plans to introduce a National Clinical Director for Dermatology. However, NHS England has established a clinical reference group for specialised dermatology to bring together clinical experts, patients and carers to share best practice and improve services for patients.</p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb grouped question UIN 224232 224234 question first answered 23/02/2015 17:01:55 answering member 1439 label Biography information for Norman Lamb
tabling member	4029 label Biography information for Lilian Greenwood

179332

registered interest
date	11/02/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Strategic Clinical Networks
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, when the next review of strategic clinical networks will be undertaken; and if he will consider the merits of creating a dermatology-focused strategic clinical network.
tabling member constituency	Nottingham South
tabling member printed	Lilian Greenwood
uin	224234
answer	answer is ministerial correction date of answer 23/02/2015 answer text <p>Since 1 April 2013, NHS England has published information factsheets for a range of purposes. The main factsheet resource for commissioners has been produced to provide the costs and benefits of 25 specific interventions to reduce premature deaths:</p><p> </p><p> </p><p> </p><p><a href="http://www.england.nhs.uk/ourwork/forward-view/sop/red-prem-mort/factsheets/" target="_blank">www.england.nhs.uk/ourwork/forward-view/sop/red-prem-mort/factsheets/</a></p><p> </p><p> </p><p> </p><p>Although there are currently no plans to produce a commissioning factsheet for dermatology, National Institute for Health and Care Excellence guidance in areas such as eczema and psoriasis continues to help commissioners to deliver high quality dermatological care.</p><p> </p><p> </p><p> </p><p>With regard to strategic clinical networks (SCNs), the first SCNs were chosen by NHS England using criteria developed with input from a broad range of stakeholders. These are initial groupings and it is expected that they will be expanded in the future. NHS England is undertaking a review of the role, purpose and function of the sub-regional infrastructure that it funds, which is focussed on supporting commissioners and providers to improve the quality of services including SCNs. This review is ongoing and is expected to reach its conclusions by the end of March.</p><p> </p><p> </p><p> </p><p>NHS England currently has no plans to introduce a National Clinical Director for Dermatology. However, NHS England has established a clinical reference group for specialised dermatology to bring together clinical experts, patients and carers to share best practice and improve services for patients.</p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb grouped question UIN 224232 224258 question first answered 23/02/2015 17:01:54 answering member 1439 label Biography information for Norman Lamb
tabling member	4029 label Biography information for Lilian Greenwood

178987

registered interest
date	10/02/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Mental Health Services: Children
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how many children and young people were diagnosed with a mental health problem in A&E in each year since 2009-10.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Luciana Berger
uin	224067
answer	answer is ministerial correction date of answer 23/02/2015 answer text <p>The information is in the table:</p><p> </p><p> </p><p> </p><table><tbody><tr><td><p>Year</p></td><td><p>2009-10</p></td><td><p>2010-11</p></td><td><p>2011-12</p></td><td><p>2012-13</p></td><td><p>2013-14</p></td></tr><tr><td><p>A&amp;E Attendances</p></td><td><p>8,358</p></td><td><p>9,328</p></td><td><p>11,614</p></td><td><p>13,655</p></td><td><p>17,278</p></td></tr><tr><td><p>FAEs</p></td><td><p>11,909</p></td><td><p>12,417</p></td><td><p>12,361</p></td><td><p>11,994</p></td><td><p>12,126</p></td></tr></tbody></table><p> </p><p> </p><p> </p><p>The table shows both the number of attendances in accident and emergency (A&amp;E) in which the A&amp;E diagnosis was 'psychiatric conditions' and the number of Finished Admission Episodes (FAEs) in which the primary diagnosis was ‘mental and behavioural disorders’.</p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb grouped question UIN 224066 question first answered 23/02/2015 16:51:09 answering member 1439 label Biography information for Norman Lamb
tabling member	4036 label Biography information for Luciana Berger

178989

registered interest
date	10/02/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Mental Health Services: Children
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how many children and young people were admitted to hospital due to mental health problems in each year since 2009-10.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Luciana Berger
uin	224066
answer	answer is ministerial correction date of answer 23/02/2015 answer text <p>The information is in the table:</p><p> </p><p> </p><p> </p><table><tbody><tr><td><p>Year</p></td><td><p>2009-10</p></td><td><p>2010-11</p></td><td><p>2011-12</p></td><td><p>2012-13</p></td><td><p>2013-14</p></td></tr><tr><td><p>A&amp;E Attendances</p></td><td><p>8,358</p></td><td><p>9,328</p></td><td><p>11,614</p></td><td><p>13,655</p></td><td><p>17,278</p></td></tr><tr><td><p>FAEs</p></td><td><p>11,909</p></td><td><p>12,417</p></td><td><p>12,361</p></td><td><p>11,994</p></td><td><p>12,126</p></td></tr></tbody></table><p> </p><p> </p><p> </p><p>The table shows both the number of attendances in accident and emergency (A&amp;E) in which the A&amp;E diagnosis was 'psychiatric conditions' and the number of Finished Admission Episodes (FAEs) in which the primary diagnosis was ‘mental and behavioural disorders’.</p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb grouped question UIN 224067 question first answered 23/02/2015 16:51:09 answering member 1439 label Biography information for Norman Lamb
tabling member	4036 label Biography information for Luciana Berger

178998

registered interest
date	10/02/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Motor Neurone Disease
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what recent assessment he has made of the effectiveness of the diagnosis and treatment of motor neurone disease.
tabling member constituency	South Down
tabling member printed	Ms Margaret Ritchie
uin	224071
answer	answer is ministerial correction date of answer 23/02/2015 answer text <p>Motor neurone disease (MND) is a rare incurable neurodegenerative condition and there are estimated to be up to 5,000 people with MND in the United Kingdom. In its early stages the disease can be difficult to diagnose because the symptoms a patient may present with, such as fatigue, clumsiness and muscle weakness are shared with more common, less serious conditions. No two people with MND will be affected in exactly the same way and there is no one test to diagnose the condition.</p><p> </p><p> </p><p> </p><p>To support general practitioners (GPs) to spot the potential symptoms of MND, the Royal College of General Practitioners (RCGPs) and the MND Association have worked together to produce a ‘Red Flag Tool’ which sets out key signs of MND to help GPs to identify suspected cases and refer them promptly to a neurologist for appropriate investigation. The RCGP and British Medical Journal have also both produced MND e-learning courses which together cover both signs and symptoms as well disease management.</p><p> </p><p> </p><p> </p><p>All services for people with MND should be commissioned as a specialised service in line with NHS England’s neurosciences service specification. This sets out what providers must have in place to deliver high quality specialised neurological care.</p><p> </p><p>Specialist MND care can include a range of services such as counselling and emotional support, respiratory care, speech and language therapy, physiotherapy, respiratory secretion management, neurorehabilitation, physiotherapy and palliative care. Drugs can be used for symptom management, but riluzole is the only pharmacological drug licensed in the UK to slow the progression of MND.</p><p> </p><p> </p><p> </p><p>Finally, the Department has asked the National Institute for Health and Care Excellence to produce a clinical guideline on MND. Development is currently underway and the guideline is anticipated for publication in February 2016.</p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb question first answered 23/02/2015 17:03:17 answering member 1439 label Biography information for Norman Lamb
tabling member	4130 label Biography information for Baroness Ritchie of Downpatrick

178999

registered interest
date	10/02/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Multiple Sclerosis
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what recent assessment he has made of the effectiveness of the diagnosis and treatment of multiple sclerosis.
tabling member constituency	South Down
tabling member printed	Ms Margaret Ritchie
uin	224072
answer	answer is ministerial correction date of answer 23/02/2015 answer text <p>The National Institute for Health and Care Excellence (NICE) guidance <em>Multiple sclerosis: management of multiple sclerosis in primary and secondary care</em>, updated in October 2014, states that around 100,000 people in the United Kingdom have multiple sclerosis (MS). Estimates from studies on annual incidence are more uncertain, and vary between 2,500 and 6,000 newly diagnosed cases each year. About 85 out of 100 people with MS have relapsing–remitting MS (RRMS) where periods of stability (remission) are followed by episodes when there are exacerbations of symptoms (relapses). About 10 to 15 out of 100 people with MS have primary progressive MS where symptoms gradually develop and worsen over time from the start, without ever experiencing relapses and remissions.</p><p> </p><p> </p><p> </p><p>The guidance sets out a range of initial assessments a clinician should make including testing of vision and blood tests before referral to a consultant neurologist who can confirm or exclude a diagnosis of MS, subject to investigation. The guidance makes a range of recommendations on the pharmacological and non-pharmacological management of MS. NICE has recommended a number of drugs for the treatment of MS and is currently appraising Nerventra (laquinimod) for RRMS and ilenya (fingolimod) for primary-progressive MS. In addition over 18,000 patients have benefitted from disease-modifying treatments through the MS risk sharing scheme, established by the Department in 2002.</p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb grouped question UIN 224073 question first answered 23/02/2015 16:52:34 answering member 1439 label Biography information for Norman Lamb
tabling member	4130 label Biography information for Baroness Ritchie of Downpatrick

179002

registered interest
date	10/02/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Multiple Sclerosis
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what recent assessment he has made of trends in the rates of people being diagnosed with multiple sclerosis.
tabling member constituency	South Down
tabling member printed	Ms Margaret Ritchie
uin	224073
answer	answer is ministerial correction date of answer 23/02/2015 answer text <p>The National Institute for Health and Care Excellence (NICE) guidance <em>Multiple sclerosis: management of multiple sclerosis in primary and secondary care</em>, updated in October 2014, states that around 100,000 people in the United Kingdom have multiple sclerosis (MS). Estimates from studies on annual incidence are more uncertain, and vary between 2,500 and 6,000 newly diagnosed cases each year. About 85 out of 100 people with MS have relapsing–remitting MS (RRMS) where periods of stability (remission) are followed by episodes when there are exacerbations of symptoms (relapses). About 10 to 15 out of 100 people with MS have primary progressive MS where symptoms gradually develop and worsen over time from the start, without ever experiencing relapses and remissions.</p><p> </p><p> </p><p> </p><p>The guidance sets out a range of initial assessments a clinician should make including testing of vision and blood tests before referral to a consultant neurologist who can confirm or exclude a diagnosis of MS, subject to investigation. The guidance makes a range of recommendations on the pharmacological and non-pharmacological management of MS. NICE has recommended a number of drugs for the treatment of MS and is currently appraising Nerventra (laquinimod) for RRMS and ilenya (fingolimod) for primary-progressive MS. In addition over 18,000 patients have benefitted from disease-modifying treatments through the MS risk sharing scheme, established by the Department in 2002.</p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb grouped question UIN 224072 question first answered 23/02/2015 16:52:33 answering member 1439 label Biography information for Norman Lamb
tabling member	4130 label Biography information for Baroness Ritchie of Downpatrick